Expansion of Culture Media Product Lineup, Production Technology and Sales Organization
First written in FY2024. 3 of 4 entries say "Advanced", first in FY2025. Latest entry: 2026-07-15.
3 other companies' latest entry also says "Advanced".
- 2026-07-15AdvancedOther Disclosures
「代表的な結核菌株及び非結核性抗酸菌株において、コロニーが検出されるまでの時間を短縮することが可能となりました。」
結核研究所との共同研究により、抗酸菌検査用の新しい固形培地を開発し、結核菌の培養期間短縮、非結核性抗酸菌の発育、観察性向上を確認した。今後は臨床検体を用いた性能評価や製品化を進めるとしている。 - FY2026AdvancedAnnual report
「In November 2025, the company completed its internal review of a medium for transfecting CHO cells, scheduled for launch in the fiscal year ending March 2027, and commissioned an external specialist organisation to conduct performance testing.」
The company reports specific progress in expanding its product portfolio, with the completion of its internal review of a new product for CHO cells and the transition to external performance testing. - FY2025AdvancedAnnual report
「During the consolidated fiscal year, the company launched KBM EV Pure in July 2024 as a medium for producing exosomes, which are considered to play an important role in intercellular communication, and KBM740 in November 2024, a liquid medium for insect cells used in the development and production of biopharmaceuticals.」
The company reports specific progress in expanding its product portfolio through the launches of KBM EV Pure and KBM740. - FY2024First statedAnnual report
「The company is working to further strengthen its production technology and sales organisation in order to expand its product portfolio.」
The company plans to expand its capabilities in proprietary, custom-made and OEM products by leveraging its ability to handle customised requirements and its manufacturing technology.